Levothyroxine false claims lawsuit
Watson is enjoined from making claims that Abbott's Synthroid is not safe and effective due to FDA's denial of its citizen petition, under a preliminary injunction granted by Chicago federal court Judge David Coar July 19. Watson is considering appealing the order. Abbott filed suit against Watson in June over Watson's promotions for its FDA-approved levothyroxine product Unithroid. Watson's claims "that Synthroid will be taken off the market come August 2001" were not found to be misleading, given FDA's "ambiguous" pronouncements about the fate of unapproved products, the decision says. FDA clarified its regulatory plans for unapproved levothyroxine products in a July 12 guidance (1"The Pink Sheet" July 16, p. 16)
You may also be interested in...
An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials